Holen Sie sich die Stockscreener-App
14.28
1.99%
-0.29
Schlusskurs vom Vortag:
$14.57
Offen:
$14.56
24-Stunden-Volumen:
898.72K
Relative Volume:
0.52
Marktkapitalisierung:
$1.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.88M
KGV:
-9.232
EPS:
-1.5468
Netto-Cashflow:
$-104.72M
1W Leistung:
+0.49%
1M Leistung:
-7.63%
6M Leistung:
-56.73%
1J Leistung:
-18.40%
1-Tages-Spanne:
$13.84
$14.70
1-Wochen-Bereich:
$13.80
$14.70
52-Wochen-Spanne:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
14.28 | 1.49B | 0 | -115.88M | -104.72M | -1.5468 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Two Sigma Investments LP Sells 129,791 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint (NASDAQ:EWTX) - Seeking Alpha
Nuveen Asset Management LLC Raises Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Nuveen Asset Management LLC Acquires 158,452 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Woodline Partners LP Has $15.15 Million Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
BNP Paribas Financial Markets Makes New $883,000 Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
106,562 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Purchased by Point72 Asset Management L.P. - MarketBeat
Frazier Life Sciences Management L.P. Cuts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics’ SWOT analysis: promising rare disease pipeline faces challenges By Investing.com - Investing.com South Africa
Edgewise Therapeutics’ SWOT analysis: promising rare disease pipeline faces challenges - Investing.com Nigeria
Soleus Capital Management L.P. Acquires New Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Polar Asset Management Partners Inc. Trims Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Tang Capital Management LLC Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Deutsche Bank AG Grows Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
How to Take Advantage of moves in (EWTX) - news.stocktradersdaily.com
Northern Trust Corp Acquires 35,426 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Brokerages Set Edgewise Therapeutics, Inc. (NASDAQ:EWTX) PT at $40.22 - MarketBeat
Balyasny Asset Management L.P. Buys Shares of 23,364 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy - MSN
Ensign Peak Advisors Inc Acquires New Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 - PR Newswire
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is MPM Bioimpact LLC's 3rd Largest Position - MarketBeat
Paradigm Biocapital Advisors LP Grows Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Parkman Healthcare Partners LLC Sells 275,897 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Janus Henderson Group PLC Purchases 425,421 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
D. E. Shaw & Co. Inc. Purchases 231,023 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
J. Goldman & Co LP Increases Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Research Analysts Offer Predictions for EWTX FY2029 Earnings - MarketBeat
Granahan Investment Management LLC Sells 211,892 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Northern Trust Corp Boosts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Cubist Systematic Strategies LLC Makes New $5.86 Million Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? - Yahoo Finance
Muscle Disease Leader Edgewise Therapeutics Takes Stage at RBC Healthcare Conference - Stock Titan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by DAFNA Capital Management LLC - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Acquired by Algert Global LLC - MarketBeat
Deerfield Management Company L.P. Series C Buys 297,503 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edgewise Therapeutics Inc-Aktie (EWTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
May 02 '25 |
Sale |
16.45 |
1,551 |
25,520 |
18,521 |
| MOORE JOHN R | General Counsel |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
8,461 |
| MOORE JOHN R | General Counsel |
May 02 '25 |
Sale |
16.45 |
1,930 |
31,757 |
6,531 |
| KOCH KEVIN | President and CEO |
May 01 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
24,895 |
| KOCH KEVIN | President and CEO |
May 02 '25 |
Sale |
16.45 |
4,276 |
70,358 |
20,619 |
| Donovan Joanne M. | CMO |
May 01 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
26,775 |
| Donovan Joanne M. | CMO |
May 02 '25 |
Sale |
16.45 |
5,187 |
85,348 |
21,588 |
| Derakhshan Behrad | Chief Business Officer |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
22,046 |
| Derakhshan Behrad | Chief Business Officer |
May 02 '25 |
Sale |
16.45 |
1,691 |
27,824 |
20,355 |
| Carruthers R Michael | Chief Financial Officer |
May 01 '25 |
Option Exercise |
0.00 |
5,209 |
0 |
82,328 |
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):